The research progress of exosomes in the immune escape of prostate cancer cell

doi:10.3877/cma.j.issn.1674-3253.2025.02.003

Abstract

Abstract:

Exosome was first discovered in 1983，it was thought to be a mechanism used by cells to excrete waste in the 1990s.Recent studies have shown that exosomes carry complex components，including proteins，nucleic acids，lipids and other metabolites.Exosomes transport these complex components to nearby or distant cells，participate in cell-to-cell substance exchange and cell communication，and regulate cell homeostasis，immune response and aging.Almost all cells secrete exosomes，so exosomes are also components of the tumor microenvironment，and play an important role in tumor development，metastasis，immune response and therapy.Prostate cancer is one of the most common malignant tumors in male genitourinary system.Exosomes play the role of substance exchange and signal transmission between cells through their contents，which mediates the immune escape process of prostate cancer cells，promotes the development and metastasis of prostate cancer.This article reviews the recent research progress of exosomes in immune escape of prostate cancer cell.

Key words: Prostate cancer, Exosome, Immune escape, Immunotherapy, Tumor microenvironment(TME), Tregs cell

Yongbo Liu, Jia Guo. The research progress of exosomes in the immune escape of prostate cancer cell[J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 140-145.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2025.02.003

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2025/V19/I02/140

References 49

［1］	NoHánělová K，Raudenská M，Masařík M，et al.Protein cargo in extracellular vesicles as the key mediator in the progression of cancer［J］.Cell Commun Signal，2024，22（1）： 25.DOI： 10.1186/s12964-023-01408-6.
［2］	Kalluri R，LeBleu VS.The biology，function，and biomedical applications of exosomes［J］.Science，2020，367（6478）： eaau6977.DOI： 10.1126/science.aau6977.
［3］	Miron RJ，Zhang Y.Understanding exosomes： part 1-characterization，quantification and isolation techniques［J］.Periodontol 2000，2024，94（1）： 231-256.DOI： 10.1111/prd.12520.
［4］	de la Torre Gomez C，Goreham RV，Bech Serra JJ，et al.“Exosomics”-a review of biophysics，biology and biochemistry of exosomes with a focus on human breast milk［J］.Front Genet，2018，9： 92.DOI：10.3389/fgene.2018.00092.
［5］	Mathieu M，Martin-Jaular L，Lavieu G，et al.Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication［J］.Nat Cell Biol，2019，21（1）： 9-17.DOI：10.1038/s41556-018-0250-9.
［6］	Zhou B，Xu K，Zheng X，et al.Application of exosomes as liquid biopsy in clinical diagnosis［J］.Signal Transduct Target Ther，2020，5（1）： 144.DOI： 10.1038/s41392-020-00258-9.
［7］	Wang Y，Xiao T，Zhao C，et al.The regulation of exosome generation and function in physiological and pathological processes［J］.Int J Mol Sci，2023，25（1）： 255.DOI： 10.3390/ijms25010255.
［8］	Mortezaee K，Majidpoor J.The impact of hypoxia on extracellular vesicle secretome profile of cancer［J］.Med Oncol，2023，40（5）： 128.DOI： 10.1007/s12032-023-01995-x.
［9］	Liu Y，Shi K，Chen Y，et al.Exosomes and their role in cancer progression［J］.Front Oncol，2021，11： 639159.DOI： 10.3389/fonc.2021.639159.
［10］	Chu X，Yang Y，Tian X.Crosstalk between pancreatic cancer cells and cancer-associated fibroblasts in the tumor microenvironment mediated by exosomal microRNAs［J］.Int J Mol Sci，2022，23（17）：9512.Doi： 10.3390/ijms23179512.
［11］	Han C，Zhang C，Wang H，et al.Exosome-mediated communication between tumor cells and tumor-associated macrophages： implications for tumor microenvironment［J］.Oncoimmunology，2021，10（1）：1887552.DOI： 10.1080/2162402X.2021.1887552.
［12］	国家癌症中心，国家肿瘤质控中心前列腺癌质控专家委员会.中国前列腺癌规范诊疗质量控制指标（2022 版）［J］.中华肿瘤杂志，2022，44（10）： 1011-1016.DOI： 10.3760/cma.j.cn112152-20220803-00530.National Cancer Center，Prostate Cancer Expert Committee of National Cancer Quality Control Center.Quality control indicators of standardized diagnosis and treatment of prostate cancer in China（2022 edition）［J］.Chin J Oncol，2022，44（10）： 1011-1016.DOI：10.3760/cma.j.cn112152-20220803-00530.
［13］	Wang G，Zhao D，Spring DJ，et al.Genetics and biology of prostate cancer［J］.Genes Dev，2018，32（17-18）： 1105-1140.DOI： 10.1101/gad.315739.118.
［14］	Gong J，Chehrazi-Raffle A，Reddi S，et al.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy：a comprehensive review of registration trials and future considerations［J］.J Immunother Cancer，2018，6（1）： 8.DOI： 10.1186/s40425-018-0316-z.
［15］	王超雄，郑培宣，赵允.病理激活的中性粒细胞上表达的CD300ld 参与肿瘤免疫抑制［J］.中国细胞生物学学报，2023，45（11）： 1593-1597.DOI： 10.11844/cjcb.2023.11.0001.Wang CX，Zheng PX，Zhao Y.The CD300ld receptor on pathologically activated neutrophils is required for tumor-driven immune suppression［J］.Chin J Cell Biol，2023，45（11）： 1593-1597.DOI： 10.11844/cjcb.2023.11.0001.
［16］	Elia AR，Caputo S，Bellone M.Immune checkpoint-mediated interactions between cancer and immune cells in prostate adenocarcinoma and melanoma［J］.Front Immunol，2018，9： 1786.DOI： 10.3389/fimmu.2018.01786.
［17］	Silva JAF，Calmasini F，Siqueira-Berti A，et al.Prostate immunology：a challenging puzzle［J］.J Reprod Immunol，2020，142： 103190.DOI：10.1016/j.jri.2020.103190.
［18］	Qin S，Cao J，Ma X.Function and clinical application of exosomehow to improve tumor immunotherapy？［J］.Front Cell Dev Biol，2023，11： 1228624.DOI： 10.3389/fcell.2023.1228624.
［19］	Cui X，Fu Q，Wang X，et al.Molecular mechanisms and clinical applications of exosomes in prostate cancer［J］.Biomark Res，2022，10（1）：56.DOI： 10.1186/s40364-022-00398-w.
［20］	Klibi J，Niki T，Riedel A，et al.Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells［J］.Blood，2009，113（9）： 1957-1966.DOI： 10.1182/blood-2008-02-142596.
［21］	Paskeh MDA，Entezari M，Mirzaei S，et al.Emerging role of exosomes in cancer progression and tumor microenvironment remodeling［J］.J Hematol Oncol，2022，15（1）：83.DOI： 10.1186/s13045-022-01305-4.
［22］	Lundholm M，Schröder M，Nagaeva O，et al.Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8⁺ T cells： mechanism of immune evasion［J］.PLoS One，2014，9（9）： e108925.DOI： 10.1371/journal.pone.0108925.
［23］	Li N，Wang Y，Xu H，et al.Exosomes derived from RM-1 cells promote the recruitment of MDSCs into tumor microenvironment by upregulating CXCR4 via TLR2/NF-κ B pathway［J］.J Oncol，2021，2021： 5584406.DOI： 10.1155/2021/5584406.
［24］	Luo JQ，Yang TW，Wu J，et al.Exosomal PGAM1 promotes prostate cancer angiogenesis and metastasis by interacting with ACTG1［J］.Cell Death Dis，2023，14（8）： 502.DOI： 10.1038/s41419-023-06007-4.
［25］	Xu F，Wang X，Huang Y，et al.Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8⁺ T cell［J］.Cell Rep，2023，42（11）： 113424.DOI： 10.1016/j.celrep.2023.113424.
［26］	Naito Y，Yoshioka Y，Yamamoto Y，et al.How cancer cells dictate their microenvironment： present roles of extracellular vesicles［J］.Cell Mol Life Sci，2017，74（4）： 697-713.DOI： 10.1007/s00018-016-2346-3.
［27］	Webber J，Steadman R，Mason MD，et al.Cancer exosomes trigger fibroblast to myofibroblast differentiation［J］.Cancer Res，2010，70（23）： 9621-9630.DOI： 10.1158/0008-5472.CAN-10-1722.
［28］	Sun C，Mezzadra R，Schumacher TN.Regulation and function of the PD-L1 checkpoint［J］.Immunity，2018，48（3）： 434-452.DOI：10.1016/j.immuni.2018.03.014.
［29］	Guan H，Peng R，Fang F，et al.Tumor-associated macrophages promote prostate cancer progression via exosome-mediated miR-95 transfer［J］.J Cell Physiol，2020，235（12）： 9729-9742.DOI： 10.1002/jcp.29784.
［30］	鲍子戌，周海胜.肿瘤细胞的EMT 与免疫逃逸的研究进展［J］.生命的化学，2017，37（6）： 980-985.DOI： 10.13488/j.smhx.20170617.Bao ZX，Zhou HS.The research progress of the EMT and immune escape of cancer cells［J］.Chem Life，2017，37（6）： 980-985.DOI：10.13488/j.smhx.20170617.
［31］	Gaballa R，Ali HEA，Mahmoud MO，et al.Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate cancer cells by inducing epithelial-mesenchymal transition［J］.Cancers，2020，12（8）： 2300.DOI： 10.3390/cancers12082300.
［32］	Lin CJ，Yun EJ，Lo UG，et al.The paracrine induction of prostate cancer progression by caveolin-1［J］.Cell Death Dis，2019，10（11）：834.DOI： 10.1038/s41419-019-2066-3.
［33］	Pegtel DM，Gould SJ.Exosomes［J］.Annu Rev Biochem，2019，88：487-514.DOI： 10.1146/annurev-biochem-013118-111902.
［34］	Kim J，Morley S，Le M，et al.Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells： potential effects on the tumor microenvironment［J］.Cancer Biol Ther，2014，15（4）： 409-418.DOI： 10.4161/cbt.27627.
［35］	Li SL，An N，Liu B，et al.Exosomes from LNCaP cells promote osteoblast activity through miR-375 transfer［J］.Oncol Lett，2019，17（5）： 4463-4473.DOI： 10.3892/ol.2019.10110.
［36］	Zhao H，Yang L，Baddour J，et al.Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism［J］.eLife，2016，5： e10250.DOI： 10.7554/eLife.10250.
［37］	Shao X，Hua S，Feng T，et al.Hypoxia-regulated tumor-derived exosomes and tumor progression： a focus on immune evasion［J］.Int J Mol Sci，2022，23（19）： 11789.DOI： 10.3390/ijms231911789.
［38］	Josson S，Gururajan M，Sung SY，et al.Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis［J］.Oncogene，2015，34（21）： 2690-2699.DOI：10.1038/onc.2014.212.
［39］	Zhang Y，Zhao J，Ding M，et al.Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis［J］.J Exp Clin Cancer Res，2020，39（1）： 282.DOI： 10.1186/s13046-020-01761-1.
［40］	Vardaki I，Corn P，Gentile E，et al.Radium-223 treatment increases immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment［J］.Clin Cancer Res，2021，27（11）： 3253-3264.DOI： 10.1158/1078-0432.CCR-20-4790.
［41］	Gururajan M，Josson S，Chu GC，et al.miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer［J］.Clin Cancer Res，2014，20（24）： 6559-6569.DOI： 10.1158/1078-0432.CCR-14-1784.
［42］	Zhang G，Liu Y，Yang J，et al.Inhibition of circ_0081234 reduces prostate cancer tumor growth and metastasis via the miR-1/MAP 3 K1 axis［J］.J Gene Med，2022，24（8）： e3376.DOI： 10.1002/jgm.3376.
［43］	Abd Elmageed ZY，Yang Y，Thomas R，et al.Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes［J］.Stem Cells，2014，32（4）： 983-997.DOI： 10.1002/stem.1619.
［44］	Gong C，Zhang X，Shi M，et al.Tumor exosomes reprogrammed by low pH are efficient targeting vehicles for smart drug delivery and personalized therapy against their homologous tumor［J］.Adv Sci，2021，8（10）： 2002787.DOI： 10.1002/advs.202002787.
［45］	Yi M，Niu M，Xu L，et al.Regulation of PD-L1 expression in the tumor microenvironment［J］.J Hematol Oncol，2021，14（1）： 10.DOI：10.1186/s13045-020-01027-5.
［46］	André F，Chaput N，Schartz NEC，et al.Exosomes as potent cellfree peptide-based vaccine.I.Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells［J］.J Immunol，2004，172（4）： 2126-2136.DOI： 10.4049/jimmunol.172.4.2126.
［47］	Shi X，Sun J，Li H，et al.Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer［J］.Prostate，2020，80（11）： 811-823.DOI： 10.1002/pros.23996.
［48］	Wang D，Wan Z，Yang Q，et al.Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes［J］.Drug Deliv，2022，29（1）： 702-713.DOI：10.1080/10717544.2022.2044937.
［49］	Poggio M，Hu T，Pai CC，et al.Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory［J］.Cell，2019，177（2）： 414-427.e13.DOI： 10.1016/j.cell.2019.02.016.

[1]	Xiaobo Zhang, Te Ba, Ruijuan Huang, Hongyu Wang. Research progress on the mechanism of mesenchymal stem cell-derived exosomes on improving acute lung injury [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2025, 20(01): 81-85.
[2]	Fanrun Zeng, Yongyong Lin, Jun Wang. Advances in the mechanisms of mesenchymal stem cell-derived exosomes promoting wound angiogenesis [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2025, 20(01): 86-89.
[3]	Zhongtao Zhang, Jiale Gao, Hongwei Yao. Current Status and Prospects of Neoadjuvant Chemoradiotherapy Combined with Immunotherapy for Locally Advanced Rectal Cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 119-122.
[4]	Hongwei Yao, Liting Sun, Shi Wu, Wenlong Su, Jiale Gao, Zhengyang Yang, Guocong Wu, Zhongtao Zhang. Exploration and practice of neoadjuvant radiotherapy combined with immunotherapy for locally advanced rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 123-127.
[5]	Qianyu Wang, Junfeng Du, Shiyong Li. Breakthroughs and challenges in neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 128-131.
[6]	Yonghong Li, Jun Wang, Hengjun Xiao. Interpretation updates of the 2025 NCCN Guidelines on diagnosis and treatment for prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 129-133.
[7]	Haowei Qiu, Zhen Xu, Zexiu Xiao, Yan Xia, Gaofeng Zha, Jun Pang. Updates of mRNA vaccine research for prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 134-139.
[8]	Tianlong Luo, Qingqing He, Hai Huang. Long-term comprehensive management of chronic urinary dysfunction and the practice of sustainable rehabilitation [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(01): 21-26.
[9]	Fan Feng, Wenliang Ma, Xiang Dong, Jun Pan, Weidong Gan, Hongqian Guo. An evidence-based analysis in early postoperation： robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(01): 83-87.
[10]	Honghao Zhu, Xinxiang Fan. Multidisciplinary consultation on difficult cases in Guangdong Urological Association （Phase 18）： female primary urethral carcinoma [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(01): 120-124.
[11]	Botao Chen, Kuan Hu, Xianhai Mao. Tumor microenvironment and systematic treatment of gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 203-208.
[12]	Chongyang Wang, Wenwen Hua, Li Wei, Yinghe Qiu, Facai Yang, Hanjuan Li. Research progress in immunotherapy combined with locoregional therapy for advanced hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 302-307.
[13]	Zhipeng Sun, Bin Shu, Liang Wang, Xin Huang, Pengfei Wang, Guangxin Li, Xiaojuan Wang, Gong Li, Shizhong Yang. Safety and efficacy of radiotherapy combined with targeted neoadjuvant immunotherapy for intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 92-96.
[14]	Weinan Li, Gang Yang, Yongfu Xiong, Qiang Li, Jingdong Li. Preliminary experience of ALPPS after TACE combined with targeted immunotherapy for middle stage and advanced liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 97-101.
[15]	Shanshan Wang, Haitao Zhao. Conversion surgery strategies for biliary tract cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 1-5.

Please choose a citation manager

Content to export